Keyphrases
Texas
100%
Tolerability
100%
Long-term Treatment
100%
Lovastatin
100%
Atherosclerosis Prevention
100%
Air Force
100%
Prevention Studies
100%
Coronary Atherosclerosis
100%
Major Coronary Events
41%
Treatment Group
25%
High-density Lipoprotein Cholesterol (HDL-C)
25%
Low-density Lipoprotein Cholesterol (LDL-C)
25%
Group Differences
25%
Confidence Interval
16%
Placebo
16%
Relative Risk
16%
Stable Angina
16%
Number of Events
16%
Coronary Artery Disease
8%
Cardiovascular Disease
8%
Myocardial Infarction
8%
Statins
8%
Muscle Symptoms
8%
Clinically Significant
8%
Primary Prevention
8%
Postmenopausal Women
8%
Risk Reduction
8%
Primary Prevention Trials
8%
Coronary Heart Disease Prevention
8%
Sudden Cardiac Death
8%
Elevated Liver Enzymes
8%
Clinical Evidence
8%
Consistent Patterns
8%
Cholesterol-lowering
8%
Nonfatal Myocardial Infarction
8%
Coronary Revascularization
8%
Reducing Agent
8%
Pharmacology, Toxicology and Pharmaceutical Science
Tolerability
100%
Mevinolin
100%
Coronary Artery Atherosclerosis
100%
High Density Lipoprotein Cholesterol
25%
Low Density Lipoprotein Cholesterol
25%
Placebo
16%
Heart Infarction
16%
Ischemic Heart Disease
16%
Unstable Angina Pectoris
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Liver Enzyme
8%
Reducing Agent
8%
Muscle Cancer
8%
Sudden Cardiac Death
8%
Cardiovascular Disease
8%
Medicine and Dentistry
Lovastatin
100%
High Density Lipoprotein Cholesterol
25%
Low Density Lipoprotein Cholesterol
25%
Cardiovascular System
16%
Myocardial Infarction
16%
Primary Prevention
16%
Placebo
16%
Ischemic Heart Disease
16%
Unstable Angina Pectoris
16%
Cardiovascular Disease
8%
Statin
8%
Risk Reduction
8%
Sudden Cardiac Death
8%
Heart Muscle Revascularization
8%
Reducing Agent
8%
Liver Enzyme
8%
Muscle Cancer
8%
Postmenopause
8%